

Available online at www.sciencedirect.com



Tetrahedron Letters

Tetrahedron Letters 45 (2004) 7987-7990

Reversible 5'-end biotinylation and affinity purification of synthetic RNA

Shiyue Fang and Donald E. Bergstrom*

Department of Medicinal Chemistry and Molecular Pharmacology, 201 S University Street, Purdue University, West Lafayette, IN 47907, USA Walther Cancer Institute, Indianapolis, IN 46208, USA

> Received 29 July 2004; revised 17 August 2004; accepted 2 September 2004 Available online 21 September 2004

Abstract—A reversible biotinylation phosphoramidite was synthesized and incorporated onto the 5'-end of an oligoribonucleotide on a solid phase synthesizer. After cleavage and deprotection, the crude synthetic oligomer mixture was incubated with NeutrAvidin[®] coated microspheres, and the failure sequences removed by washing with a buffer followed by treating the microspheres with tetrabutylammonium fluoride to give a high quality unmodified full-length oligoribonucleotide. © 2004 Elsevier Ltd. All rights reserved.

Besides wide application in biology and medicine for nonradioacitve labeling of biopolymers,1-3 the strong interaction (association noncovalent constant $10^{15} M^{-1}$) between biotin and streptavidin or avidin has been proved to be useful for efficient isolation of biotinylated DNA from complex mixtures.^{4–6} Typically, the mixture containing the biotinylated target is incubated with streptavidin or avidin coated microspheres, then, nonbiotinylated materials are removed by washing with buffer followed by recovering purified target molecules from the microspheres. In order to obtain unmodified DNA after affinity isolation, a special reversible linker between biotin and target is required. The reported linkers suitable for such a purpose include the acid-cleavable triphenylmethyl alkyl ether linkage reported by Gildea et al.⁴ and the photocleavable o-nitrobenzyl alkyl phosphate diester linkage reported by Rothschild and co-workers.⁵ Although successful in certain applications, these linkers have shortcomings such as inconvenient preparation, long cleavage time under acidic conditions and potential damage of biomolecules caused by exposure to UV irradiation.^{7–9} Recently, we reported the preparation of two phosphoramidites con-


taining a diisopropylsilyl acetal linkage, and their use for reversible biotinylation, phosphorylation and affinity purification of synthetic DNA.^{10,11} We demonstrated that the phosphoramidites could be efficiently coupled onto the 5'-end of an oligodeoxyribonucleotide on a solid phase synthesizer, and that the linkage was completely stable under synthetic and cleavage/ deprotection conditions. The biotinylated full-length DNA could be efficiently attached to NeutrAvidin[®] coated microspheres, failure sequences could be completely removed by simple washing with buffers, and high quality unmodified DNA could be recovered by treating with fluoride ion. As it is well known, oligoribonucleotide synthesis is generally less efficient than oligodeoxyribonucleotide synthesis, and thus, generates more failure sequences. Moreover, extreme caution is required to handle RNA because of ubiquitous RNAse. These factors coupled with the higher hydrophilicity of RNA make it more difficult to purify. Consequently, an efficient, simple RNA purification method should be valuable to the scientific community. Here we report the synthesis of a reversible biotinylation ribonucleotide phosphoramidite, its incorporation onto the 5'-end of an oligoribonucleotide on a solid phase synthesizer, and the application of this biotinylation methodology in affinity purification of synthetic RNA.

As shown in Scheme 1, the biotinylation phosphoramidite 1 was conveniently prepared from the known biotinyl alcohol 2^{10} in two steps. Thus, 2 (1 equiv),

Keywords: Oligoribonucleotide; RNA; Solid phase synthesis; Reversible biotinylation; Phosphoramidite; Avidin; Affinity purification; Diisopropylsilylacetal linker.

^{*} Corresponding author. Tel.: +1 765 494 6275; fax: +1 765 494 6275; e-mail: bergstrom@purdue.edu

^{0040-4039/\$ -} see front matter @ 2004 Elsevier Ltd. All rights reserved. doi:10.1016/j.tetlet.2004.09.019




Scheme 1. Synthesis of the reversible biotinylation phosphoramidite 1.

imidazole (1 equiv) and diisopropylethylamine (DIEA, 3 equiv) in dry DMF was cooled on an ice bath, diisopropyldichlorosilane was added, and the solution was stirred at 0 °C for 1 h and at room temperature for 4h. The resulting solution was added slowly to a solution of 2'-O-ACE-uridine (**3**, 1 equiv)¹² and imidazole (1 equiv) in DMF via a cannula at 0 °C, and the mixture was stirred at the same temperature for 4h. Partition between CH₂Cl₂ and 5% NaHCO₃ and flash chromatography (SiO₂, EtOAc/MeOH/Et₃N = 95:4:1) gave **4** as a white foam in 91% yield.¹³ The vacuum dried **4** (1 equiv) was dissolved in CH₂Cl₂ and degassed by argon followed by the addition of phosphinylation agent **5** (1.3 equiv) via a syringe, and tetrazole (1.1 equiv) under positive argon pressure. After stirring at room temperature for 12 h, the mixture was partitioned between

CH₂Cl₂ and 5% NaHCO₃. Purification by flash chromatography (SiO₂ pretreated with CHCl₃/THF/ Et₃N = 3:2:0.5, then washed with CHCl₃/THF = 3:2; after loading the sample, eluted with CHCl₃/ THF = 3:2) gave product **1** as a white foam in 52% yield.¹⁴

To test this biotinylation and affinity purification strategy, the short 5'-end biotinylated oligoribonucleotide **6** (Scheme 2) was next synthesized on a solid phase synthesizer at Dharmacon, Inc. on a 1 μ mol scale.^{15,16} The synthesis was carried out on a high cross-linked polystyrene support using the 2'-O-ACE protected phosphoramidites illustrated in Figure 1 and biotinylation phosphoramidite **1** as building blocks under standard conditions. After complete deprotection and cleavage,^{15,16}



Scheme 2. Removal of biotin to generate unmodified RNA.




Figure 1. Phosphoramidite monomers used for RNA synthesis.

the crude oligoribonucleotide (10% of the 1 µmol synthesis), which contains the full-length oligomer, failure sequences, and other impurities, was incubated with NeutrAvidin[®] gel (600 μ L) in PBS buffer (300 μ L) at room temperature for 2h.17 Because the failure sequences generated in each synthetic cycle were capped with large excess of acetic anhydride, only the full-length oligoribonucleotide was biotinylated by the phosphoramidite 1. As a result, only the desired RNA was attached to the microsphere through the noncovalent interaction between biotin and NeutrAvidin[®], and the failure sequences and other impurities were removed by washing with PBS buffer $(300 \,\mu\text{L} \times 3)$ and water $(500 \,\mu\text{L} \times 3)$. After drying on a SpeedVac, the pure full-length unmodified RNA 7 (Scheme 2) was recovered from the gel by treating with tetrabutylammonium fluoride (TBAF, 1M, THF) at room temperature for 12h with gentle shaking followed by quenching by equal volume Tris-HCl buffer (100 mM, pH7.4), and washing with water $(300 \,\mu\text{L} \times 5)$. In order to estimate the recovery yield of oligoribonucleotide from the microspheres, in addition to the full-length sequence recovered from gel, the failure sequences removed by washing were also collected, both were desalted by a NAPTM-25 column,¹⁸ and their quantities were determined by UV measurement at 260nm, respectively. From these data, the recovery yield of RNA was estimated to be about 80%.

The efficacy of the affinity purification was next evaluated by 20% denatured (8M urea) polyacrylamide gel electrophoresis (PAGE). In Figure 2, lane a is the crude RNA treated with TBAF (1 M, THF, 200 μ L, *N*-methylpyrolidinone, 200 μ L, rt, 12h; 10% of the 1 μ mol synthesis treated, 1% of which loaded).¹⁹ Lane b is untreated




Figure 2. PAGE analysis of the results of NeutrAvidin[®] coated microspheres mediated affinity purification of synthetic RNA. See text for details.

crude RNA (same amount loaded). As can be seen, the biotinylated full-length RNA 6 runs much slower than the unmodified full-length RNA 7 and failure sequences, and the diisopropylsilylacetal linkage is not completely stable under deprotection/cleavage conditions. In order to estimate the degree of premature breakage, a separate preparative denatured PAGE was used to separate 6 and 7, ²⁰ and both were extracted from the gel with NH₄OAc buffer (0.1 M). UV measurement indicated that more than 70% 6 retained their biotin moiety during cleavage and deprotection. Lane c is recovered failure sequences removed from the Neutr-Avidin[®] gel (concentrated on SpeedVac, desalted on a NAPTM-25 column, 1% loaded) during the affinity purification. This lane demonstrated the high efficiency of the attachment of biotinyl RNA 6 to the avidin coated microsphere as 6 is not visible. Lane d is the affinity purified full-length unmodified RNA 7 (1% loaded), and shows that the failure sequences have been completely removed yielding pure RNA.

In summary, we prepared a novel reversible biotinylation phosphoramidite, and successfully incorporated it onto the 5'-end of oligoribonucleotide on a solid phase synthesizer. To the best of our knowledge, this represents the first chemical biotinylation of the 5'-end of RNA using a reversible linker, which, upon cleavage, affords unmodified RNA. We demonstrated that biotinylated full-length RNA could be efficiently attached to NeutrAvidin[®] coated microspheres by simple incubation in a buffer, failure sequences, and other impurities could be removed by simple washing, and high quality RNA could be conveniently obtained by cleavage from the microsphere.

Acknowledgements

Grant support from the National Institutes of Health (GM53155) and the Showalter Trust Fund is gratefully acknowledged. Assistance from the National Cancer Institute Grant (P30 CA23168) awarded to Purdue University is also gratefully acknowledged.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2004.09.019.

References and notes

- McInnes, J. L.; Symons, R. H. Nucleic Acid Probes. In Preparation and Detection of Nonradioactive Nucleic Acid and Oligonucleotide Probes; Symons, R. H., Ed.; CRC: Boca Raton, FL, 1989; pp 33–80.
- Langer, P. R.; Waldrop, A. A.; Ward, D. C. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 6633–6637.
- Urdea, M. S.; Warner, B. D.; Running, J. A.; Stempien, M.; Clyne, J.; Horn, T. Nucleic Acids Res. 1988, 16, 4937– 4956.

- 4. Gildea, B. D.; Coull, J. M.; Koster, H. *Tetrahedron Lett.* **1990**, *31*, 7095–7098.
- Olejnik, J.; Krzymanska-Olejnik, E.; Rothschild, K. J. Nucleic Acids Res. 1996, 24, 361–366.
- Shimkus, M.; Levy, J.; Herman, T. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 2593–2597.
- 7. Greenberg, M. M. Tetrahedron 1995, 51, 29-38.
- 8. Greenberg, M. M.; Gilmore, J. L. J. Org. Chem. 1994, 59, 746–753.
- Cadet, J.; Vigny, P. Bioorganic Photochemistry. In *The Photochemistry of Nucleic Acids*; Morrison, H., Ed.; John Wiley & Sons: New York, NY, 1990; Vol. 1, pp 170–184.
- Fang, S.; Bergstrom, D. E. Nucleic Acids Res. 2003, 31, 708–715.
- 11. Fang, S.; Bergstrom, D. E. *Bioconjugate Chem.* 2003, 14, 80–85.
- 12. 2'-O-ACE-uridine 3 was purchased from Dharmacon, Inc.
- 13. Biotinylurindine 4: $R_f = 0.3$ (EtOAc/MeOH = 9:1); IR (thin film, cm^{-1}) v 3309 (br), 2945, 2864, 1735, 1685, 1653, 1247, 1111, 1051; ¹H NMR (CDCl₃, 300 MHz) δ 0.97-1.11 (m, 14H), 1.28 (s, 6H), 1.32 (s, 9H), 1.46-1.87 (m, 8H), 2.05 (s, 3H), 2.06 (s, 3H), 2.19-2.30 (m, 4H), 3.02-3.09 (m, 2H), 3.22-3.26 (m, 1H), 3.34-3.43 (m, 4H), 3.45-3.68 (m, 8H), 3.75-4.34 (m, 14H), 5.20-5.24 (m, 1H), 5.59, (s, 1H), 5.66 (d, J = 8.4 Hz, 1H), 5.96 (d, J = 2.1 Hz, 1H), 7.39 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 7.94 (d, J = 8.1 Hz, 1H); ¹³C NMR (CDCl₃, 300 MHz) δ 1.85, 13.26, 13.41, 17.69, 20.85, 25.40, 27.79, 27.95, 29.69, 29.78, 31.15, 31.66, 34.94, 35.62, 38.24, 39.09, 39.26, 40.01, 55.15, 57.44, 61.01, 62.49, 62.71, 62.79, 63.07, 68.16, 69.78, 70.04, 73.74, 84.17, 88.23, 101.97, 112.37, 116.52, 124.48, 128.97, 131.79, 140.15, 150.44, 154.91, 156.36, 163.67, 169.91, 170.92, 173.18, 173.61. MS (ESI, M-H) calcd for C57H89N6O19SSi 1221.56, found 1221.35.
- 14. Phosphoramidite 1: $R_f = 0.2$ (CHCl₃/THF = 1:1); ¹H NMR (CDCl₃, 300 MHz) δ 0.97–1.12 (m, 14H), 1.12–

1.22 (m, 12H), 1.25-1.28 (m, 6H), 1.32 (s, 9H), 1.47-1.87 (m, 8H), 2.05–2.06 (m, 6H), 2.18–2.31 (m, 4H), 3.05–3.08 (m, 2H), 3.22–3.49 (m, 10H), 3.50–3.70 (m, 8H), 3.72–3.98 (m, 15H), 4.32-4.43 (m, 1H), 5.21-5.25 (m, 1H), 5.48 (s, 0.5H), 5.56 (s, 0.5H), 5.67 (d, J = 8.1 Hz, 1H), 5.99 (d, J = 2.7 Hz, 0.5 H), 6.02 (d, J = 3.9 Hz, 0.5 H), 7.39 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H), 7.85 (d, J =7.5 Hz, 1H); ¹³C NMR (CDCl₃, 300 MHz) δ 10.06, 13.10, 13.67, 17.64, 17.75, 17.88, 20.85, 21.19, 24.64, 24.75, 25.37, 25.60, 29.80, 30.31, 31.15, 31.61, 34.22, 34.94, 35.51, 38.25, 39.08, 39.24, 40.05, 42.82, 42.92, 43.08, 45.46, 55.08, 57.37, 61.23, 61.48, 61.65, 61.88, 62.47, 62.68, 63.17, 67.93, 69.79, 69.86, 70.01, 70.09, 73.68, 83.46, 84.26, 87.85, 88.97, 101.89, 111.79, 111.96, 124.48, 125.50, 128.23, 128.97, 131.75, 135.80, 140.70, 140.94, 150.21, 150.30, 151.50, 154.88, 156.29, 163.58, 169.95, 170.87, 173.06, 173.33; $^{31}\mathrm{P}$ NMR (CDCl₃, 300MHz) δ 168.30, 168.57.

- 15. Scaringe, S. A.; Wincott, F. E.; Caruthers, M. H. J. Am. Chem. Soc. 1998, 120, 11820–11821.
- 16. Dahl, B. H.; Bjergarde, K.; Henriksen, L.; Dahl, O. Acta Chem. Scand. 1990, 44, 639-641.
- NeutrAvidin[®] gel was purchased from Pierce Biotechnology, Inc. PBS buffer: 136.9mM NaCl, 2.7mM KCl, 10.1mM Na₂HPO₄, 1.8mM KH₂PO₄, adjusted to pH7.0 with HCl.
- NAPTM-25 column was purchased from Amersham Biosciences. Desalting was performed following manufacturesuggested procedure.
- 19. The gel was imaged on a Molecular Dynamics Storm (860) system after staining in a SYBR[®] Gold (purchased from Molecular Probes, Inc.) solution in 1× TBE buffer (1:10,000) at rt for 30 min.
- RNAs 6 and 7 were identified with MALDI mass spectra. Biotinyl RNA 6: calcd 5287, found 5289. Unmodified RNA 7: calcd 4687, found 4687.